Table 1. Patients’ characteristics.
| Characteristic | Total (n) | % |
|---|---|---|
| Total number of patients | 56 | 100 |
| Median age (years–range) | 70 | 48–85 |
| Gender | ||
| Male | 38 | 67.9 |
| Female | 18 | 32.1 |
| Histology | ||
| Adenocarcinoma | 44 | 78.6 |
| Squamous-cell carcinoma | 6 | 10.7 |
| Not specified | 6 | 10.7 |
| Smoking history | ||
| Never | 11 | 19.6 |
| Former | 32 | 57.1 |
| Current | 13 | 23.2 |
| Performance status | ||
| 0 | 38 | 67.8 |
| 1 | 10 | 17.9 |
| 2 | 6 | 10.7 |
| 3 | 2 | 3.6 |
| Number of metastaticsites | ||
| 1–2 | 20 | 35.7 |
| 3–4 | 31 | 55.4 |
| ≥5 | 5 | 8.9 |
| First line treatment | ||
| Chemotherapy | 41 | 73.2 |
| Targeted therapies | 12 | 21.4 |
| Immunotherapy | 3 | 5.4 |
| EGFR status | ||
| Mutateda | 11 | 19.6 |
| Wild type | 37 | 66.1 |
| Unknown | 8 | 14.3 |
| KRAS status | ||
| Mutatedb | 13 | 23.2 |
| Wild type | 25 | 44.7 |
| Unknown | 18 | 32.1 |
| ALK status | ||
| Rearranged | 2 | 3.6 |
| Wild type | 37 | 66.1 |
| Unknown | 17 | 30.3 |
| ROS1 status | 1.8 | |
| Rearranged | 1 | 32.1 |
| Wild type | 18 | 66.1 |
| Unknown | 37 | |
| Triple negativec | 9 | 16.1 |
aEGFR mutations included: exon 18 = 1 (9.0%); exon 19 = 4 (36.4%); exon 20 = 2(18.2%); exon 21 = 4 (36.4%); bKRAS mutations included: codon 12 = 13(100%); cTriple negative included EGFR/KRAS/ALK/ROS1 wild-type patients.